Published in Am J Ophthalmol on November 06, 2009
The role of the optical coherence tomography in identifying shape and size of idiopathic epiretinal membranes. Br J Ophthalmol (2012) 1.41
Comparative evaluation of anatomical and functional outcomes using brilliant blue G versus triamcinolone assisted ILM peeling in macular hole surgery in Indian population. Graefes Arch Clin Exp Ophthalmol (2011) 1.08
Critical involvement of extracellular ATP acting on P2RX7 purinergic receptors in photoreceptor cell death. Am J Pathol (2011) 1.02
Dynamic increase in extracellular ATP accelerates photoreceptor cell apoptosis via ligation of P2RX7 in subretinal hemorrhage. PLoS One (2013) 0.93
A preliminary study of Heavy Brilliant Blue G for internal limiting membrane staining in macular hole surgery. Indian J Ophthalmol (2012) 0.90
Vitreomacular traction syndrome. J Ophthalmic Vis Res (2012) 0.79
Synthesis, staining properties, and biocompatibility of a new cyanine dye for ILM peeling. Graefes Arch Clin Exp Ophthalmol (2012) 0.78
Chromovitrectomy: an update. J Ophthalmic Vis Res (2014) 0.78
Novel dyes in intraocular surgery. Am J Ophthalmol (2010) 0.75
Differential autophagic effects of vital dyes in retinal pigment epithelial ARPE-19 and photoreceptor 661W cells. PLoS One (2017) 0.75
Osmolarity and spectrophotometric property of brilliant blue green define the degree of toxicity on retinal pigment epithelial cells exposed to surgical endoilluminator. Clin Ophthalmol (2016) 0.75
Effect of vital dyes on retinal pigmented epithelial cell viability and apoptosis: implications for chromovitrectomy. Ophthalmologica (2013) 0.75
Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods (2004) 3.53
Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol (2008) 2.52
Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol (2007) 2.51
Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology (2007) 2.38
Dynamic mechanical properties of human lenses. Exp Eye Res (2005) 2.19
Long-term results after bare sclera pterygium resection with excimer smoothing and local application of mitomycin C. Cornea (2005) 2.13
Efficient mitochondrial biogenesis drives incomplete penetrance in Leber's hereditary optic neuropathy. Brain (2013) 2.08
Natural history of drusen morphology in age-related macular degeneration using spectral domain optical coherence tomography. Ophthalmology (2011) 1.96
Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina (2007) 1.68
Stepwise replication identifies a low-producing lymphotoxin-alpha allele as a major risk factor for early-onset leprosy. Nat Genet (2007) 1.56
A simple technique to fixate the bullet pipe and perform bimanual vitreous surgery. Indian J Ophthalmol (2004) 1.55
Primary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema: pilot study of the Pan-American Collaborative Retina Study Group. J Cataract Refract Surg (2007) 1.51
Clinical use and research applications of Heidelberg retinal angiography and spectral-domain optical coherence tomography - a review. Clin Experiment Ophthalmol (2009) 1.49
Clinical evaluation of simultaneous confocal scanning laser ophthalmoscopy imaging combined with high-resolution, spectral-domain optical coherence tomography. Acta Ophthalmol (2010) 1.44
Retinal prosthesis for the blind. Surv Ophthalmol (2002) 1.43
Effect of oxygenated intraocular irrigation solutions on the electroretinogram after vitrectomy. Retina (2007) 1.43
Decreased visual acuity associated with cystoid macular edema in neovascular age-related macular degeneration. Arch Ophthalmol (2002) 1.39
Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months. Ophthalmology (2009) 1.38
Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy. Br J Ophthalmol (2011) 1.33
Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol (2012) 1.32
Subretinal implantation of retinal pigment epithelial cells derived from human embryonic stem cells: improved survival when implanted as a monolayer. Invest Ophthalmol Vis Sci (2013) 1.30
Extensive investigation of a large Brazilian pedigree of 11778/haplogroup J Leber hereditary optic neuropathy. Am J Ophthalmol (2003) 1.27
Optical coherence tomography and indocyanine green angiography findings in acute syphilitic posterior placoid choroidopathy: case report. Arq Bras Oftalmol (2010) 1.26
Combined intravitreal anti-vascular endothelial growth factor (Avastin) and photodynamic therapy to treat retinal juxtapapillary capillary haemangioma. Acta Ophthalmol (2009) 1.22
Weight gain measured at 6 weeks after birth as a predictor for severe retinopathy of prematurity: study with 317 very low birth weight preterm babies. Graefes Arch Clin Exp Ophthalmol (2008) 1.22
Visual outcomes following macular translocation with 360-degree peripheral retinectomy. Arch Ophthalmol (2002) 1.21
Corneal reconstruction with tissue-engineered cell sheets composed of human immature dental pulp stem cells. Invest Ophthalmol Vis Sci (2009) 1.20
Investigation of the retinal biocompatibility of acid violet for chromovitrectomy. Graefes Arch Clin Exp Ophthalmol (2013) 1.20
Choroidal neovascularization treated with intravitreal injection of bevacizumab (Avastin) in angioid streaks. Acta Ophthalmol Scand (2006) 1.19
Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res (2007) 1.19
Effect of needle type and injection technique on pain level and vitreal reflux in intravitreal injection. J Ocul Pharmacol Ther (2011) 1.17
Endophthalmitis after pars plana vitrectomy: results of the Pan American Collaborative Retina Study Group. Retina (2011) 1.17
Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-month follow-up -- the SOLO study. Acta Ophthalmol (2013) 1.16
Ophthalmologic findings in a large pedigree of 11778/Haplogroup J Leber hereditary optic neuropathy. Am J Ophthalmol (2004) 1.15
Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group results. Ophthalmology (2009) 1.15
Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol (2010) 1.14
The use of vital dyes in ocular surgery. Surv Ophthalmol (2009) 1.13
Effects of subretinal injections of indocyanine green, trypan blue, and glucose in rabbit eyes. Ophthalmology (2007) 1.13
Is the location of valsalva hemorrhages submembranous or subhyaloidal? Am J Ophthalmol (2006) 1.12
A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life. Cancer Res (2010) 1.10
Current treatment modalities for exudative retinal hamartomas secondary to tuberous sclerosis: review of the literature. Acta Ophthalmol Scand (2007) 1.09
Autofluorescence and angiographic findings of retinal astrocytic hamartomas in tuberous sclerosis. Ophthalmologica (2005) 1.08
Fluidics in a dual pneumatic ultra high-speed vitreous cutter system. Ophthalmologica (2012) 1.07
Dyes in ocular surgery: principles for use in chromovitrectomy. Am J Ophthalmol (2009) 1.06
Comparison of geographic atrophy measurements from the OCT fundus image and the sub-RPE slab image. Ophthalmic Surg Lasers Imaging Retina (2013) 1.05
Ligand binding assays in the 21st century laboratory: recommendations for characterization and supply of critical reagents. AAPS J (2012) 1.04
Chromovitrectomy: a new field in vitreoretinal surgery. Graefes Arch Clin Exp Ophthalmol (2004) 1.04
Testing the effects of the dye acid violet-17 on retinal function for an intraocular application in vitreo-retinal surgery. Graefes Arch Clin Exp Ophthalmol (2014) 1.03
Transient serous retinal detachment in classic and occult choroidal neovascularization after photodynamic therapy. Am J Ophthalmol (2005) 1.03
Vitreous traction after Ozurdex injection. J Ocul Pharmacol Ther (2012) 1.02
Visual recovery after scleral buckling surgery in macula-off rhegmatogenous retinal detachment. Ophthalmologica (2006) 1.01
Therapeutic monoclonal antibodies in ophthalmology. Prog Retin Eye Res (2008) 1.00
Intravitreal injection of ziv-aflibercept in patient with refractory age-related macular degeneration. Ophthalmic Surg Lasers Imaging Retina (2015) 1.00
STRATUS optical coherence tomography in unilateral colobomatous excavation of the optic disc and secondary retinoschisis. Graefes Arch Clin Exp Ophthalmol (2004) 0.99
Confocal scanning laser ophthalmoscopy findings in chronic solar retinopathy. Ophthalmic Surg Lasers Imaging (2008) 0.99
Status of serum VEGF and ICAM-1 and its association with external limiting membrane and inner segment-outer segment junction disruption in type 2 diabetes mellitus. Mol Vis (2013) 0.98
Age-related changes in vitreous mobility as measured by video B scan ultrasound. Exp Eye Res (2002) 0.98
Implications of high level pseudogene transcription in Mycobacterium leprae. BMC Genomics (2009) 0.98
Influence of ocular volume and lens status on pharmacokinetics and duration of action of intravitreal vascular endothelial growth factor inhibitors. Retina (2015) 0.98
Electrical stimulation in normal and retinal degeneration (rd1) isolated mouse retina. Vision Res (2006) 0.97
Vital dyes for chromovitrectomy. Curr Opin Ophthalmol (2007) 0.97
Mechanisms of intravitreal toxicity of indocyanine green dye: implications for chromovitrectomy. Retina (2007) 0.96
Tunneled scleral incision to prevent vitreal reflux after intravitreal injection. Am J Ophthalmol (2007) 0.96
Perspective on fluid and solid dynamics in different pars plana vitrectomy systems. Am J Ophthalmol (2011) 0.95
Intravitreal injection of bevacizumab for cystoid macular edema in retinitis pigmentosa. Acta Ophthalmol Scand (2007) 0.95
Twelve-month safety and visual acuity results from a feasibility study of intraocular, epiretinal radiation therapy for the treatment of subfoveal CNV secondary to AMD. Retina (2009) 0.95
Vital dyes and light sources for chromovitrectomy: comparative assessment of osmolarity, pH, and spectrophotometry. Invest Ophthalmol Vis Sci (2008) 0.94
Photodynamic therapy for exudative hamartoma in tuberous sclerosis. Arch Ophthalmol (2006) 0.93
Intravitreal Bevacizumab (Avastin(®)) for Diabetic Retinopathy at 24-months: The 2008 Juan Verdaguer-Planas Lecture. Curr Diabetes Rev (2010) 0.93
Intravitreal bevacizumab for inflammatory choroidal neovascularization: results from the Pan-American Collaborative Retina Study Group at 24 months. Retina (2011) 0.93
Effects of intravitreal triamcinolone acetonide injection with and without preservative. Br J Ophthalmol (2007) 0.92
Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture. J Ophthalmol (2011) 0.92
Square root transformation of geographic atrophy area measurements to eliminate dependence of growth rates on baseline lesion measurements: a reanalysis of age-related eye disease study report no. 26. JAMA Ophthalmol (2013) 0.91
Residual internal limiting membrane after epiretinal membrane peeling: results of the Pan-American Collaborative Retina Study Group. Retina (2013) 0.91